drugset / Trial / NCT02334254
Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety for the combination of Rivaroxaban and Ticagrel versus triple antithrombotic regimen (Vitamin K Antagonist (VKA), Clopigogrel and Aspirin) in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention (PCI).
Timeline
- Start
- 2013-08
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 5 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |
| Comparator | Warfarin | Small molecule | — | — |